Effects of vildagliptin, a DPP-4 inhibitor, in elderly diabetic patients with mild cognitive impairment

Borzì, Antonio Maria; Condorelli, G; Biondi, Antonio; Burzotta, Francesco; Vicari, Enzo; Buscemi, Carola; Luca, S. De; Vacante, Marco

doi:10.1016/j.archger.2019.06.001

Cited by 29 publications

(26 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sample was also insufficient for analysis of SGLT2 inhibitors and GLP1 agonists, but their relationships with memory relative to other diabetes drug classes will be of great interest in future investigations given recent findings of reduced dementia incidence associated with these drug classes in addition to DPP4 inhibitors and metformin 32 . Previous studies suggested that DPP4 inhibitors may have beneficial effects on cognition in patients with diabetes and MCI; 7,8 however, significant associations were not identified here in aMCI, possibly due to a relatively small and heterogeneous sample. The present results cannot be generalized to people without T2DM.…”

Section: Discussionmentioning

confidence: 85%

“…Metformin has been associated with a lower dementia risk; 4 however, its effects on memory have been inconsistent. 5,6 Relatively few clinical studies have assessed associations between memory and dipeptidyl peptidase-4 (DPP4) inhibitor use, 7,8 although sitagliptin, a DPP4…”

Section: Introductionmentioning

confidence: 99%

“…Metformin has been associated with a lower dementia risk; 4 however, its effects on memory have been inconsistent 5,6 . Relatively few clinical studies have assessed associations between memory and dipeptidyl peptidase‐4 (DPP4) inhibitor use, 7,8 although sitagliptin, a DPP4 inhibitor, was associated with improved general cognition in people with T2DM and AD, 9 and was shown to slow Aβ accumulation in transgenic mouse models of AD 10 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status

Ouk

Wong

et al. 2020

Alzheimer's & Dementia

View full text Add to dashboard Cite

Introduction: Few studies have examined memory decline among patients with type 2 diabetes using different oral hypoglycemic drugs. Methods: Participants with normal cognition (NC) or Alzheimer's disease (AD) dementia using a hypoglycemic medication (2005 to 2019) were identified from the National Alzheimer's Coordinating Center database. Delayed memory was assessed using the Wechsler Memory Scale Revised-Logical Memory test. Associations between oral This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status

Ouk

Wong

et al. 2020

Alzheimer's & Dementia

View full text Add to dashboard Cite

show abstract

“…Borzì et al [171] Retrospective study of the effect of vildagliptin on cognitive function in older diabetic adults with MCI.…”

Section: Antidiabeticsmentioning

confidence: 99%

Metabolic Syndrome: Is It Time to Add the Central Nervous System?

et al. 2021

View full text Add to dashboard Cite

Metabolic syndrome (MS) is a set of cardio-metabolic risk factors that includes central obesity, hyperglycemia, hypertension, and dyslipidemias. The syndrome affects 25% of adults worldwide. The definition of MS has evolved over the last 80 years, with various classification systems and criteria, whose limitations and benefits are currently the subject of some controversy. Likewise, hypotheses regarding the etiology of MS add more confusion from clinical and epidemiological points of view. The leading suggestion for the pathophysiology of MS is insulin resistance (IR). IR can affect multiple tissues and organs, from the classic “triumvirate” (myocyte, adipocyte, and hepatocyte) to possible effects on organs considered more recently, such as the central nervous system (CNS). Mild cognitive impairment (MCI) and Alzheimer’s disease (AD) may be clinical expressions of CNS involvement. However, the association between MCI and MS is not understood. The bidirectional relationship that seems to exist between these factors raises the questions of which phenomenon occurs first and whether MCI can be a precursor of MS. This review explores shared pathophysiological mechanisms between MCI and MS and establishes a hypothesis of a possible MCI role in the development of IR and the appearance of MS.

show abstract

“…[ 12 ] Another retrospective also shows that vildagliptin in addition to metformin showing a protecting role on cognitive functioning compared to the metformin only group in elderly diabetic patients with MCI. [ 13 ] In a Real-World Population-Based Cohort Study, DPP-4i used decreases the risk of dementia compared to sulfonylureas (SU) used in elderly patients with T2DM. [ 14 ]…”

Section: Introductionmentioning

confidence: 99%

Effect of dipeptidyl peptidase-4 inhibitors inhibitor on cognitive dysfunction in diabetes

Liu¹,

Wang²,

Deng³

et al. 2020

Medicine

View full text Add to dashboard Cite

show abstract

Effects of vildagliptin, a DPP-4 inhibitor, in elderly diabetic patients with mild cognitive impairment

Cited by 29 publications

References 32 publications

Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status

Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status

Metabolic Syndrome: Is It Time to Add the Central Nervous System?

Effect of dipeptidyl peptidase-4 inhibitors inhibitor on cognitive dysfunction in diabetes

Contact Info

Product

Resources

About